Candel Therapeutics Stock Cash Per Share
| CADL Stock | USD 4.43 0.08 1.77% |
Candel Therapeutics fundamentals help investors to digest information that contributes to Candel Therapeutics' financial success or failures. It also enables traders to predict the movement of Candel Stock. The fundamental analysis module provides a way to measure Candel Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Candel Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Cash Per Share | 1.22 | 1.49 |
Candel | Cash Per Share |
Candel Therapeutics Company Cash Per Share Analysis
Candel Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Candel Therapeutics Cash Per Share | 3.00 X |
Most of Candel Therapeutics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Candel Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Candel Cash Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Candel Therapeutics is extremely important. It helps to project a fair market value of Candel Stock properly, considering its historical fundamentals such as Cash Per Share. Since Candel Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Candel Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Candel Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Candel Cash Per Share Historical Pattern
Today, most investors in Candel Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Candel Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Candel Therapeutics cash per share as a starting point in their analysis.
Candel Therapeutics Cash Per Share |
| Timeline |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
Candel Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, Candel Therapeutics has a Cash Per Share of 3.0 times. This is 31.03% lower than that of the Biotechnology sector and 30.72% lower than that of the Health Care industry. The cash per share for all United States stocks is 40.12% higher than that of the company.
Candel Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Candel Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Candel Therapeutics could also be used in its relative valuation, which is a method of valuing Candel Therapeutics by comparing valuation metrics of similar companies.Candel Therapeutics is currently under evaluation in cash per share category among its peers.
Candel Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Candel Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Candel Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Candel Fundamentals
| Return On Equity | -4.81 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 147.88 M | ||||
| Shares Outstanding | 32.48 M | ||||
| Shares Owned By Insiders | 30.39 % | ||||
| Shares Owned By Institutions | 22.53 % | ||||
| Number Of Shares Shorted | 2.1 M | ||||
| Price To Book | 30.41 X | ||||
| Price To Sales | 436.42 X | ||||
| Revenue | 31 K | ||||
| Gross Profit | (20.66 M) | ||||
| EBITDA | (37.43 M) | ||||
| Net Income | (37.94 M) | ||||
| Cash And Equivalents | 86.78 M | ||||
| Cash Per Share | 3.00 X | ||||
| Total Debt | 22.76 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 14.86 X | ||||
| Book Value Per Share | 0.44 X | ||||
| Cash Flow From Operations | (34.24 M) | ||||
| Short Ratio | 7.72 X | ||||
| Earnings Per Share | (1.73) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 42 | ||||
| Beta | -0.87 | ||||
| Market Capitalization | 134.29 M | ||||
| Total Asset | 41.2 M | ||||
| Retained Earnings | (137.03 M) | ||||
| Working Capital | 22.61 M | ||||
| Net Asset | 41.2 M |
About Candel Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Candel Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Candel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Candel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Candel Therapeutics Piotroski F Score and Candel Therapeutics Altman Z Score analysis. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Revenue Per Share 0.001 | Return On Assets (0.52) | Return On Equity (4.81) |
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.